Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and valleys. Even if there’s a city off in the distance to your right, it does ...

April 3 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone ...

Goldman updates coverage across major U.S. drugmakers, citing exclusivity risks, pricing power, and pipeline outlooks ...

Eli Lilly's manufacturing plant in Limerick. President Trump said he would shortly unveil tariffs on pharmaceutical imports. (Paulo Nunes dos Santos/Bloomberg News) Stocks in drugmakers sold off ...

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Apheris’ consortium of pharma companies is partnering with OpenFold3 — Columbia professor Mohammed AlQuraishi’s open-source dupe of AlphaFold3 — to train the model on AbbVie and Johnson ...

Upgrading J&J (NYSE:JNJ) to Buy from Neutral ... However, Haider downgraded AbbVie (NYSE:ABBV) to Neutral from Buy, and trimmed its 12-month price target to $194 from $212 per share, arguing ...